

COMMERCIAL COVERAGE



The only fresh human amniotic membrane tissue product, Affinity® retains native living cells, an intact extracellular matrix, and a variety of growth factors and cytokines.¹⁻⁶

100M + Lives covered by commercial medical policies

PAYER	COVERAGE		
Amerihealth	Medical Necessity		
Aultcare Health Plan	Medical Necessity		
BC Capital Blue PA	DLEU		
BCBS Capital Health Plan FL	DLEU		
BCBS CareFirst (DC, MD, VA)	DLEU		
BCBS Federal Employees	DLEU		
BCBS HCSC (IL, NM, OK, TX, MT)	DLEU		
BCBS Highmark (PA, DE, WV, Western NY)	DLEU		
BCBS HMSA HI	DLEU		
BCBS of AL	DLEU		
BCBS of AR	DLEU		
BCBS of AZ	DLEU		
BCBS of FL	DLEU		
BCBS of Kansas City	DLEU		

PAYER	COVERAGE		
BCBS of KS	DLEU		
BCBS of LA	DFU		
BCBS of MA	DLEU		
BCBS of MI	DLEU		
BCBS of MN	DLEU		
BCBS of MS	DLEU		
BCBS of NC	Burns		
BCBS of ND	DLEU		
BCBS of NE	DLEU		
BCBS of RI	DLEU		
BCBS of SC	DLEU		
BCBS of TN	DLEU		
BCBS of VT	DLEU		
BCBS of (WA, AK)	DLEU		

PAYER	COVERAGE	
BCBS Wellmark (IA, SD)	DLEU	
Blue Cross ID	DLEU	
Blue Cross Independence PA	Medical Necessity	
Blue Shield CA	DLEU	
Blue Shield Regence (WA ID OR UT)	DLEU	
CareSource	Medicaid Guidelines	
Centene Health (All states)	Varies by state	
Emblem	Medical Necessity	
Geisinger	Medical Necessity	
Health Alliance Plan of Michigan (HAP)	DLEU	
HealthPartners	Medical Necessity	
Presbyterian Health System	Follows Medicare LCD	

This is a sample of insurers and is not an exhaustive list.

DFU=diabetic foot ulcer; VLU=venous leg ulcer; DLEU=diabetic lower extremity ulcer.

The coverage information provided shall not be construed as a statement, promise, or a guarantee that reimbursement will be received. Reimbursement requirements are subject to change at any time. Check with your local payer regularly.

References: 1. Data on file. DR-0010. Organogenesis Inc. **2.** McQuilling JP, et al. *Int Wound J.* 2017;14(6):993-1005. **3.** Data on file. AF_DR-0014. Organogenesis Inc. **4.** Niknejad H, et al. *Eur Cells Mater.* 2008;15:88-99. **5.** Data on file. DR-0007. Organogenesis Inc. **6.** Mamede AC, et al. *Cell Tissue Res.* 2012;349(2):447-458.





COMMERCIAL COVERAGE



The gold standard for more than 20 years, Apligraf® remains the only bioengineered, bilayered living cell-based product with FDA approval for healing both VLUs and DFUs.1-9

UNMATCHED Coverage for patients regardless of their insurance*

of **commercial** medical policies cover Apligraf treatment for VLUs and DFUs⁸ of **Medicare** contractors cover Apligraf treatment for VLUs and DFUs⁸

	VLU COVERAGE	DFU COVERAGE
Aetna	V	V
Anthem	V	V
BCBS Federal Employees Program	V	V
BCBS Highmark	V	V
Cigna	V	V
Excellus	V	V
Humana	V	V
Medica	V	V
United Healthcare	V	V

This is a sample of major insurers and is not an exhaustive list.

The coverage information provided shall not be construed as a statement, promise, or guarantee that reimbursement will be received. Reimbursement requirements are subject to change at any time. Check with your local payer regularly.

*Insurance coverage varies by payer and is subject to change at any time. Confirm with your current applicable payer policies for up-to-date Apligraf coverage requirements and policies.

Please refer to the Apligraf Package Insert for complete prescribing information. Please refer to Apligraf Handling and Storage

References: 1. Stone RC, et al. *Sci Transl Med.* 2017:9(371), 2. Apligraf [package insert]. Canton, MA; Organogenesis Inc; 2017.
3. Marston WA, et al. *Wound Repair Regen.* 2014;22(3):334-340. 4. Treadwell T, et al. *Adv Wound Care.* 2018;7(3):69-76. 5. Sabolinski ML, et al. *J Comp Eff Res.* 2018;7(8):797-805. 6. Veves A, et al. *Diabetes Care.* 2001;24(2):290-295. 7. Kirsner RS, et al. *Wound Repair Regen.* 2015;23(5):737-744. 8. Data on file. Organogenesis Inc. 9. Falanga V, et al. *Arch Dermatol.* 1998;134(3):293-300.



